Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation

Androgens exert growth inhibitory effects on estrogen receptor and progesterone receptor-negative breast cancer cell lines that show androgen receptor expression. These laboratory findings may be translated into inexpensive alternative therapies for hormone receptor-negative invasive breast cancers. Our aim was to systematically evaluate androgen receptor expression by immunohistochemistry in invasive breast cancers. Androgen receptor (clone AR441, Dako) expression was analyzed on 189 well-characterized consecutive invasive breast carcinomas represented with threefold redundancy on tissue microarrays. Androgen receptor expression was semi-quantitated using a histochemical score-like method and a score >10 was considered positive. Of the 189 consecutive invasive breast cancers, 151 (80%) were positive and 38 (20%) were negative for androgen receptor. The majority (95%) of estrogen receptor-positive tumors were also androgen receptor positive. Of the estrogen receptor-negative tumors, androgen receptor reactivity was seen in 3 of 30 (10%) triple-negative cases and in 5/8 (63%) estrogen receptor-negative/progesterone receptor-negative/HER2+ cases. Six of eight estrogen receptor-negative/androgen receptor-positive cases showed apocrine differentiation. Androgen receptor expression in estrogen receptor-positive cases was associated with smaller tumor size (P=0.0001), lower Nottingham grade (P=0.002) and less frequent tumor cell necrosis (P=0.0001). Androgen receptor expression in estrogen receptor-negative tumors was associated with lower Nottingham grade (P=0.005) and apocrine differentiation (P=0.039). In conclusion, most estrogen receptor-positive breast tumors also express androgen receptor. Androgen receptor expression in estrogen receptor-negative/progesterone receptor-negative/HER2+ tumors (which commonly show apocrine differentiation) and a subset of triple - negative apocrine tumors suggest that these tumors together comprises the ‘molecular apocrine’ group described previously. However, these findings should be further confirmed on larger series of triple-negative and estrogen negative/progesterone negative/HER2+ tumors. Androgen receptor-targeted therapy in estrogen/progesterone receptor-negative tumors may provide an inexpensive alternative to usual high-dose chemotherapy with or without trastuzumab.

[1]  K. Calhoun,et al.  A New Hormonal Therapy for Estrogen Receptor–Negative Breast Cancer , 2007, World Journal of Surgery.

[2]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Bergh,et al.  Identification of molecular apocrine breast tumours by microarray analysis , 2005, Breast Cancer Research.

[4]  D. Keefe,et al.  Trastuzumab‐associated cardiotoxicity , 2002, Cancer.

[5]  G. Bratthauer,et al.  Androgen Receptor Expression Along with Loss of bcl‐2, ER, and PR Expression in Benign and Malignant Apocrine Lesions of the Breast: Implications for Therapy , 1996 .

[6]  V. Kuenen-Boumeester,et al.  Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer , 1992, International journal of cancer.

[7]  S. Swain,et al.  Therapeutic Strategies for Triple-Negative Breast Cancer , 2008, Cancer journal.

[8]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[9]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[10]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Agrawal,et al.  Androgen receptors as a prognostic and predictive factor in breast cancer. , 2008, Folia histochemica et cytobiologica.

[13]  Rohit Bhargava,et al.  Histopathologic variables predict Oncotype DX™ Recurrence Score , 2008, Modern Pathology.

[14]  A. Selim,et al.  Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors. , 1999, Journal of clinical pathology.

[15]  W. Gerald,et al.  Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer , 2009, Clinical Cancer Research.

[16]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[17]  F. Vizoso,et al.  Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors , 2008, BMC Cancer.

[18]  Katsunobu Sakurai,et al.  Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers , 2008, International Journal of Clinical Oncology.

[19]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[20]  Luke Hughes-Davies,et al.  A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. , 2008, Neoplasia.

[21]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[22]  Richard Zellars,et al.  Invasive breast cancer. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Denk,et al.  Androgen receptors frequently are expressed in breast carcinomas , 2003, Cancer.

[25]  Z. Nahleh.  Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. , 2008, Future oncology.

[26]  Paul E Swanson,et al.  Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. , 2003, American journal of clinical pathology.

[27]  G. Azabdaftari.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2009 .

[28]  G. Colditz,et al.  Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer , 2008, Breast Cancer Research.

[29]  J. Isola.  Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors , 1993, The Journal of pathology.

[30]  S. Conzen.  Minireview: nuclear receptors and breast cancer. , 2008, Molecular endocrinology.

[31]  Z. Gatalica,et al.  Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. , 1997, Pathology, research and practice.

[32]  B. Anderson,et al.  Androgens and androgen receptors: A clinically neglected sector in breast cancer biology , 2007, Journal of surgical oncology.

[33]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[34]  J. Baselga,et al.  The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 , 2008, Nature Clinical Practice Oncology.

[35]  J. Flickinger,et al.  Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. , 2009, International journal of clinical and experimental pathology.

[36]  D. Dabbs,et al.  Estrogen and Progesterone Receptors in Breast Carcinoma: Quantitation is Therapeutically Important , 2008 .

[37]  Takashi Suzuki,et al.  Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations. , 2008, Endocrine journal.

[38]  W. Gerald,et al.  An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen , 2006, Oncogene.

[39]  L. Horn,et al.  Androgen receptors are frequently expressed in mammary and extramammary Paget's disease , 2005, Modern Pathology.

[40]  V. Jordan,et al.  Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. , 2008, Advances in experimental medicine and biology.

[41]  K. Calhoun,et al.  Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. , 2004, Archives of surgery.

[42]  F. Akiyama,et al.  Expression of GCDFP‐15 and AR decreases in larger or node‐positive apocrine carcinomas of the breast , 2005, Histopathology.

[43]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  K. Calhoun,et al.  The effect of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression. , 2003, American journal of surgery.